Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history.
A Common Diabetes Pill May Also Protect Your Heart From Failure
This secondary analysis of a phase 3b randomized clinical trial evaluated once-daily oral semaglutide versus placebo in 9,650 participants w…
For millions living with type 2 diabetes and a struggling heart, a medication they might already be taking could offer a powerful, two-in-on…
Pressure-controlled volume-guaranteed ventilation improved diaphragmatic function and reduced weakness in diabetic patients undergoing laparoscopic colorectal surgery.
New Ventilation Mode Helps Diaphragm in Diabetics
This randomized controlled trial enrolled 80 patients with Type 2 diabetes scheduled for elective laparoscopic colorectal surgery. The study…
A new ventilation mode protects diaphragm strength in diabetic patients after surgery, reducing breathing complications compared to standard…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes tablet now helps control blood sugar while also lowering the risk of heart failure hospitalization for adults with heart dise…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new pill for type 2 diabetes that also helps protect the heart.
The FDA has approved dapagliflozin tablets for two indications in adults with type 2 diabetes mellitus: to improve glycemic control and to r…
A new FDA-approved pill for type 2 diabetes now helps lower blood sugar while also reducing the risk of hospitalization for heart failure.
FDA Approves Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets for Type 2 Diabetes and Related Risks
FDA approves a new once-daily pill for type 2 diabetes that may also help protect the heart and kidneys.
The FDA has approved dapagliflozin and metformin hydrochloride extended-release tablets as an adjunct to diet and exercise to improve glycem…
A new once-daily pill for type 2 diabetes may protect the heart and kidneys from serious problems like heart attacks and worsening kidney di…
PPARα rs6008845 genotype modifies fenofibrate benefit for vascular events in type 2 diabetes
Genetic variant linked to diabetes risks and fenofibrate benefits in FIELD study
This RCT substudy of 8,159 adults with type 2 diabetes examined the PPARα rs6008845 genotype and fenofibrate treatment. Participants carryin…
A specific gene variant increases diabetes complication risks, but fenofibrate treatment benefits remain consistent across all genetic group…
Elevated plasma phenylalanine associated with obesity, type 2 diabetes, and cancer risk.
High plasma phenylalanine linked to obesity, diabetes, and cancer risk
This systematic review examines epidemiological and mechanistic evidence regarding elevated plasma phenylalanine in metabolic disorders. The…
High blood phenylalanine is linked to obesity, type 2 diabetes, and cancer risk by blocking insulin signals and damaging mitochondria.
Finerenone linked to improved KDIGO risk categories in T2D and CKD patients
Does finerenone help kidney risk categories improve in diabetes patients compared to placebo?
A post hoc subanalysis of an RCT in patients with type 2 diabetes and chronic kidney disease found finerenone therapy was associated with a …
Patients with diabetes and kidney disease taking finerenone were much more likely to see their kidney risk category improve and less likely …
Urinary podocin and nephrin show poor short-term prediction of DKD progression in type 2 diabetes
Could a single urine test predict kidney failure in one year? The answer is no.
A retrospective cohort study of 119 adults with type 2 diabetes and DKD found that single baseline measurements of urinary podocin, nephrin,…
Patients with type 2 diabetes cannot rely on a single urine test to predict kidney failure over the next 12 months.
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes pill that also helps protect the heart from failure.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill approved by the FDA also lowers the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new diabetes pill that also helps protect the heart.
The FDA has approved dapagliflozin tablets for two indications: to improve glycemic control in adults with type 2 diabetes mellitus, and to …
A new daily diabetes pill now approved by the FDA helps lower blood sugar and reduces the risk of heart failure hospitalization for adults w…